Santa Barbara, CALIFORNIA3 Active Studies

Essential Tremor Clinical Trials in Santa Barbara, CALIFORNIA

Find 3 actively recruiting essential tremor clinical trials in Santa Barbara, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
245
Enrolling

Recruiting Essential Tremor Studies in Santa Barbara

About Essential Tremor Clinical Trials in Santa Barbara

Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.

There are currently 3 essential tremor clinical trials recruiting participants in Santa Barbara, CALIFORNIA. These studies are seeking a combined 245 participants. Research is being sponsored by AbbVie, Vantage Biosciences Ltd, Jaeb Center for Health Research. Clinical trial participation is free and participants receive study-related medical care at no cost.

Essential Tremor Clinical Trials in Santa Barbara — FAQ

Are there essential tremor clinical trials in Santa Barbara?

Yes, there are 3 essential tremor clinical trials currently recruiting in Santa Barbara, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Santa Barbara?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Barbara research site will contact you about next steps.

Are clinical trials in Santa Barbara free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Santa Barbara studies also compensate for your time and travel.

What essential tremor treatments are being tested?

The 3 active trials in Santa Barbara are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.

Data updated March 2, 2026 from ClinicalTrials.gov